More on [99mTc](V)DMSA Scintigraphy in Patients with Medullary Carcinoma of the Thyroid

TO THE EDITOR: We have read with interest the letter by Hilditch et al. (1) in which they stated their continuing limited success with pentavalent technetium-99m dimercaptosuccinic acid ([99mTc]DMSA) in patients with medullary carcinoma of the thyroid (MCT). We would like to report that our experience with this radiopharmaceutical has been very encouraging. We have performed ten studies in eight patients using [99mTc] (V)DMSA prepared as previously described (2). Six of the patients were asymptomatic but had persistent hypercalcitonemia after thyroid resection for MCT, one patient was studied before and after total thyroidectomy and one patient before total thyroidectomy.

Scintigraphy was considered positive in seven patients and equivocal in one patient. Using cobalt-57 markers the areas of increased uptake were marked with an indelible ink. Biopsy (needle aspiration or surgical resection) of the sites of uptake confirmed MCT in the seven patients.

Our experience with this radiopharmaceutical is of particular interest because these patients were thought to have small volume disease with only mild hypercalcitonemia (0.13-43)




FIGURE 1
Pentavalent [99mTc]DMSA image showing increased uptake in the right anterior neck (arrow), in a patient with rising calcitonin level (serial calcitonin peak: 2.6 ng/ml; normal range <0.08 ng/ml) 24 yr after right thyroid lobectomy for MCT. Repeat neck exploration and total thyroidectomy confirmed MCT. Anterior view.

ng/ml. normal range <0.08 ng/ml). Localized recurrence and distant metastases in soft tissue (Fig. 1) and bone (Fig. 2A) were detected in these patients. The early detection of occult tumor resulted in surgical resection (three patients) and early radiotherapy (one patient) (Fig. 2).

The reason for the failure of the technique as applied by the Hilditch group is not clear since quality control checks showed the presence of [99mTc](V)DMSA in the material administered to the patients (3). As they have suggested the outcome of imaging may be affected by the stage of the disease although other factors such as heterogeneity of MCT cells and the size and location of each tumor deposit have to be considered.

Our results clearly indicate that [99mTc](V)DMSA scintigraphy can be useful in the early diagnosis of recurrent or metastatic MCT including those with small volume disease.

References

- Hilditch TE, Murray T, Connell JMC, et al. Imaging with pentavalent [99mTc]DMSA in patients with medullary cancer of the thyroid. J Nucl Med 1988; 29:1746-1747.
- Sampson CB. Preparation of ⁹⁹Tc^m(V)DMSA. Nucl Med Commun 1987; 8:184–185.
- Hilditch TE. Technetium-99m(V)-DMSA in the imaging of medullary thyroid carcinoma. J Nucl Med 1987; 28:253.

O. A. Mojiminiyi
R. Udelsman
B. J. Shepstone
N. E. Dudley
N. D. W. Soper
Radcliffe Infirmary Oxford
Oxford, England

Carbon-11-L-Methionine Uptake with PET as a Predictor of Prognosis for Bronchogenic Carcinoma Patients

TO THE EDITOR: Fujiwara et al. (1) recently studied carbon-11-L-methionine uptake into lung tumor semiquantitatively. There was a significant difference in [11 C]methionine uptake between large cell carcinoma (3.98 \pm 0.27) and squamous cell carcinoma (2.92 \pm 0.03), and thus this measurement may be applicable for study and diagnosis of lung cancer.

According to the WHO histologic typing of the lung tumor, large-cell carcinoma includes giant-cell carcinoma (2), a rare variant of large cell carcinoma (3,4). It has been well-documented that giant-cell carcinoma is a more aggressive form of lung cancer than the more common bronchogenic carcinomas; (3-5) its rapidly fatal course is usually less than 1 yr in duration, with an average of 5 mo survival following initial diagnosis. In addition, the distinctive histopathology and rapid growth of bulky tumor warrant classification as a separate clinicopathological entity (3-6).

Methionine is one of the essential amino acids. The high accumulation of ¹¹C-L-methionine in the tumor seemed to

1420 Letters to the Editor The Journal of Nuclear Medicine